Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

trointestinal-derived peptide hormone that has also been associated with reducing food intake and has been studied as an anti-obesity agent. These two gastrointestinal peptides (GLP-1 and PYY) are secreted into circulation by neuroendocrine cells (L cells) as part of a natural homeostatic mechanism that senses nutrient transit through the gastrointestinal tract. Such nutrient sensing and related mechanisms are thought to be enhanced as a result of certain types of bariatric surgery for weight loss and control of diabetes.

LX4211 treatment also produced a 50.2 mg/dL adjusted mean decrease from baseline in triglycerides, consistent with the triglyceride reduction observed in the Phase 2a study in type 2 diabetics.  In addition, LX4211, compared to placebo, produced a significant adjusted mean decrease in serum uric acid (1.52 mg/dL from baseline to last study visit, p=0.005). Serum uric acid is an emerging marker for cardiovascular risk and renal disease.  These data, together with a trend of improved blood pressure observed in the Phase 2a study, demonstrate that LX4211 has effects on multiple cardiovascular and metabolic risk factors.  Also of importance in this study was the safety of LX4211, which showed no hypoglycemia and no abdominal pain or diarrhea, consistent with the favorable safety profile associated with dual inhibition of SGLT1 and SGLT2 by LX4211 in previous clinical trials. Enrollment in Lexicon's ongoing Phase 2b study of LX4211 in patients with type 2 diabetes is on schedule, with results anticipated in the first half of 2012.

"We have now observed results from several clinical studies of LX4211 which consistently support the concept of dual SGLT1/SGLT2 inhibition for the treatment of diabetes and indicate a long-term opportunity in diabetes prevention," said Pablo Lapuerta, M.D., senior vice president of clinical development and chief medical officer. "The favorab
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Calif. , May 22, 2013  Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following ... Conference , Presentation date: Wednesday May 29, 2013 ... Jefferies 2013 Global Healthcare Conference , Presentation date: Wednesday ... A live webcast and ...
(Date:5/22/2013)...  Flagship Ventures, a leading venture capital and ... today announced the appointment of Stephane ... this role, Mr. Bancel will provide strategic counsel ... addition to working closely with companies in the ... and Chief Executive Officer of Moderna Therapeutics, a ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... ALTO, Calif., Nov. 3, 2011 Telik, Inc. (Nasdaq: ... million, or $0.05 per share, for the third quarter ended ... million, or $0.09 per share, for the comparable period in ... total operating costs and expenses were $2.9 million, compared with $4.7 ...
... Aoxing Pharmaceutical (NYSE Amex: AXN ) ... research, development, manufacturing and distribution of narcotic, pain-management, ... operating subsidiary in China, Hebei Aoxing Pharmaceutical Group ... million RMB (approximately $315,000) from the Industry and ...
Cached Medicine Technology:Telik Announces Third Quarter 2011 Financial Results 2Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China 2Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China 3
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
(Date:5/22/2013)... genomic health disparities from the University of Miami Miller ... Medicine have teamed up to hold the second annual ... in Genomic Medicine." The theme of this year,s ... government to reduce these disparities. , Despite steady improvement ... within underserved groups continue to be more vulnerable to ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2
... (HealthDay News) -- Teens undergoing treatment for alcohol or ... by groups such as Alcoholics Anonymous (AA) and Narcotics ... widely available, little research has looked at how effective ... 127 teen substance abuse-treatment outpatients (95 males, 32 females, ...
... April 16 (HealthDay News) -- Surgery for non-melanoma skin cancer ... mainly due to the increased use of a specific surgical ... in the outer layer of the skin or in skin ... according to the U.S. National Cancer Institute. More than ...
... Reinberg HealthDay Reporter , MONDAY, April 16 (HealthDay ... in the brains of people with multiple sclerosis (MS), researchers ... ONO-4641, "actually caused a reduction in relapses, which is somewhat ... said lead researcher Dr. Timothy Vollmer, a professor of neurology ...
... HealthDay Reporter , MONDAY, April 16 (HealthDay News) -- In a ... participated in the "choking game," in which blood and oxygen to ... produce a euphoric "high." What,s more, the researchers found that ... and many practiced other risky behaviors. "If kids do participate, ...
... Early symptoms of major mental illness can be ... be missed, or even ignored due to conventional wisdom ... deterioration and prolonged patterns of abnormality before diagnosing and ... waiting until someone is so ill that the psychological ...
... thought to play a crucial role in regulating cell proliferation. ... and interact with one another in intact animals., This study ... functional placenta and for balancing the effect of an E2F ... genes in a family of regulatory genes are vital for ...
Cached Medicine News:Health News:12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse 2Health News:Surgery Rates Rising for Non-Melanoma Skin Cancer: Study 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 3Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 2Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 3Health News:First contact: Early intervention key in diagnosis and treatment of serious mental illness 2Health News:2 repressor genes identified as essential for placental development 2
... Wampole EBV ELISA test panel ... assays for the determination of ... for Viral Capsid Antigen (VCA), ... Antigen (EBNA). Most Wampole EBV ...
Herpes Simplex Virus Group IgG....
Cytomegalovirus IgG ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Medicine Products: